Biomarker and method for screening increased risk of suffering from mental diseases caused by infant stage stress

Through infancy-specific expression genomics and epigenomics, the MYT1L-SYT1 interaction gene combination was determined, and the risk of mental illness caused by infancy-stress was screened, and the inability to effectively screen infants in the existing technology was solved. The problem of the risk of mental illness caused by early childhood stress has achieved accurate diagnosis of early mental illness and support for individualized treatment.

CN118910248APending Publication Date: 2024-11-08SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411206569.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art cannot effectively screen for the risk of mental illness caused by infancy stress, and lacks methods for the gene marker scheme of mental illness that is characterized by highly expressed genes in infancy and early stress affects gene expression patterns through transcription factors.

Method used

The hub genes and transcription factors were determined based on genomics and epigenomics of specifically expressed genes in infancy, and the MYT1L-SYT1 interacting gene combination was used as a screening organisms that were at risk of mental illness due to external stress stress in infancy, and the Markers, bioinformatics method was used to screen the combination of psychiatric gene markers for altered gene expression induced by early-life traumatic stress from RNA sequencing data.

Benefits of technology

The accurate screening of early mental illness and the development of diagnostic gene combinations has been achieved, the gap in the existing technology has been filled, the foundation for individualized treatment, and the accuracy of early diagnosis of mental illness has been improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910248A_ABST
    Figure CN118910248A_ABST
Patent Text Reader

Abstract

The invention relates to an application of a reagent for detecting the expression level of a biomarker in preparation of a product for screening the increase of the risk of suffering from mental diseases caused by infant stage stress, and is characterized in that the biomarker is an MYT1L-SYT1 interaction gene combination. The invention also relates to a method for screening the biomarker with increased risk of suffering from mental diseases caused by infant stage stress. A scheme for searching gene markers of mental diseases is provided for the first time on the basis of characteristic high-expression genes in the infant stage, and specifically, gene clusters which are easily influenced by transcription factors are screened out through epigenetic modification characteristics (transcription factors and chromatin modification states) by using a biological information method from RNA sequencing data of corpse brain tissues in each development stage; therefore, a mental disease gene marker combination with gene expression change induced by early wound stress is obtained and can be subsequently used for developing a gene combination for early mental disease screening.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and specifically relates to the application of a reagent for detecting the expression level of a biomarker in the preparation of a product for screening for an increased risk of developing mental illness due to stress during infancy. Background Art

[0002] In recent years, with the deepening of clinical research on mental illness, it has been discovered that mother-infant separation and infant trauma do increase the risk of developing mental illness in adulthood, which has attracted widespread attention in the academic community.

[0003] Early life stress can affect brain development. Studies have shown that stress in early life, such as maternal separation and abuse, is significantly associated with mental health problems in adulthood, such as anxiety, depression, and post-traumatic stress disorder. These early stresses can change brain development, especially affecting neural circuits related to emotion regulation and coping with stress, such as the prefrontal cortex, hippocampus, and amygdala. Several prospective longitudinal studies have found that adverse childhood experiences are closely related to mental health problems in adulthood. These studies have shown that people who have experienced childhood trauma are more likely to have various mental health problems in adulthood, including anxiety, depression, suicidal tendencies, and self-harm. Neurobiological studies based on animal models have shown that early maternal separation can cause structural and functional changes in neural circuits in the brain involved in emotions and stress responses. These changes increase the likelihood of mental illness in adulthood. In summary, these studies show that adverse experiences in early life have long-term negative effects on brain development and significantly increase the risk of mental illness in adulthood.

[0004] Genes that are highly expressed during infancy are essential for brain development. These genes play a key role in the generation, differentiation, synapse formation, and establishment and modification of neural networks, directly affecting brain development and function. Abnormal expression of these genes may lead to a variety of neurodevelopmental disorders, such as autism and attention deficit hyperactivity disorder (ADHD). During brain development, certain genes such as NeuroD1 and Nestin are highly expressed in neural stem cells and progenitor cells, and these genes regulate the generation and differentiation of neurons. Studies have shown that the high expression of these genes is essential for the generation and maturation of newborn neurons. The formation and functional modification of synapses are also important links in brain development. For example, the Synaptophysin and PSD-95 genes play a key role in the formation of presynaptic and postsynaptic structures. Synapse formation and plastic changes are the basis of learning and memory processes, and the high expression of these genes is essential for the normal development and function of synapses. Neural networks in the brain are established through complex gene regulation and signal transduction. For example, BDNF (brain-derived neurotrophic factor) plays an important role in neuronal survival, differentiation, and synaptic plasticity. Studies have found that high expression of BDNF is closely related to the growth of neurons and the stability of neural networks. There are multiple critical periods in brain development, and the high expression of certain genes during these periods is essential for specific developmental processes. For example, EGR1 and ARC genes play an important role in gene expression triggered by neural activity. These genes are highly expressed during the critical period of learning and memory, promoting synaptic plasticity and memory formation.

[0005] In summary, studying the functions and regulatory mechanisms of these highly expressed genes in infancy is of great significance for understanding the mechanisms of brain development and related diseases. The aforementioned early stress can first affect the expression and activity of transcription factors through various pathways, thereby regulating gene expression and affecting the physiological and psychological functions of the organism. This mechanism plays an important role in the occurrence and development of many diseases. The current high-throughput transcriptome quantitative technology is mature, providing a sufficient technical basis for the screening of key gene markers for infant development.

[0006] In general, the expansion of this research field has important scientific significance for improving the accuracy of early diagnosis of mental illness and the development of personalized treatment. By deeply exploring the information of key gene markers in infant development, it is expected to make new breakthroughs in the field of psychiatry and lay a solid foundation for the practice of precision medicine.

[0007] Huang et al. used 10 gene clusters with similar temporal expression patterns and identified 41 genes encoding chloride transporters and channels (GClTC) on the plasma membrane associated with brain development. It was found that 4 clusters containing 22 GClTCs were enriched in neuronal function, and GClTCs from different clusters showed different cell type preferences and anatomical heterogeneity. They also found a strong correlation between cluster genes and diseases, most of which were neurological diseases. Through this method, it was found that SLC12A2, one of the GClTCs, had a greater impact on glial cell-related diseases than on neuron-related diseases. Summary of the invention

[0008] In order to solve the above problems in the prior art, the present invention provides an application of a reagent for detecting the expression level of a biomarker in the preparation of a product for screening for an increased risk of mental illness due to stress during infancy and a screening method.

[0009] In order to achieve the above-mentioned object, the first aspect of the present invention provides an application of a reagent for detecting the expression level of a biomarker in the preparation of a product for screening for an increased risk of mental illness due to stress during infancy, wherein the biomarker is a MYT1L-SYT1 interaction gene combination. The MYT1L-SYT1 interaction gene combination can screen for potential risks of mental illness.

[0010] The second aspect of the present invention provides a method for screening biomarkers that increase the risk of mental illness due to stress in infancy and childhood. The main feature of the method is that based on the genomics and epigenomics of genes specifically expressed in infancy and childhood, hub genes and transcription factors are identified as biomarkers for screening the increased risk of mental illness due to external stress in infancy and childhood.

[0011] The present invention relates to a method for screening markers for increasing the risk of mental illness due to early life trauma based on high expression gene characteristics.

[0012] Preferably, the method comprises the steps of:

[0013] (1) Collect brain gene expression data from eight donors at different developmental stages;

[0014] (2) Data processing and screening to obtain genes with high expression in infancy and childhood;

[0015] (3) Screening for psychiatric disease risk genes among genes highly expressed during infancy and childhood;

[0016] (4) Screening for transcription factors of risk genes for neurological diseases;

[0017] (5) Use the screened core transcription factors to obtain a gene set for early diagnosis of mental illness.

[0018] The present invention involves the application of computer technology, machine learning and bioinformatics in the field of clinical marker discovery. Bioinformatics methods are used to start from RNA sequencing data of cadaveric brain tissue at various developmental stages, and through epigenetic modification characteristics (transcription factors, chromatin modification status) gene bases that are easily affected by transcription factors are screened out, thereby obtaining a combination of psychiatric gene markers that may induce gene expression changes due to early traumatic stress, which can be subsequently used to develop gene combinations for early mental illness screening.

[0019] The present invention provides a reagent for detecting the expression level of biomarkers for use in the preparation of products for screening for increased risk of mental illness due to external stress in infancy and early childhood, and a screening method. It is the first time to propose a scheme for finding genetic markers for mental illness based on characteristically highly expressed genes in infancy and early childhood. Specifically, bioinformatics methods are used to start from RNA sequencing data of cadaveric brain tissue at various developmental stages, and gene clusters that are susceptible to the influence of transcription factors are screened through epigenetic modification features (transcription factors, chromatin modification status), thereby obtaining a combination of genetic markers for mental illness in which gene expression changes are induced by early traumatic stress, which can be subsequently used to develop gene combinations for early mental illness screening. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is a core flow chart of the method of the present invention for screening biomarkers that increase the risk of developing mental illness due to external stress during infancy.

[0021] Figure 2 A is the result of using Clust to identify high-precision co-expressed gene clusters specific to eight developmental stages; Figure 2 B is the pathway enrichment analysis result diagram of cluster 3.

[0022] Figure 3 To screen and obtain a collection of genes at risk for mental illness among genes highly expressed in infancy.

[0023] Figure 4 This is a schematic diagram of the results of the present invention in which MYT1L was found to be the most important transcription factor based on ChEA3 data. DETAILED DESCRIPTION

[0024] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further described below in conjunction with specific embodiments.

[0025] At present, it is still impossible to objectively diagnose mental illnesses using genetic markers due to the pleiotropy of genes, high disease heterogeneity, and the limitations of current biological research technology. There is sufficient clinical evidence that early childhood trauma (such as maternal-infant separation and abuse) leads to an increased risk of mental illness, but there is currently no proposal to find genetic markers for mental illness based on characteristically highly expressed genes in infancy, and there is a gap in this area. In addition, there is currently no method to propose a method for early stress to affect gene expression patterns through transcription factors to implement the determination of genetic markers for mental illness.

[0026] The present invention fills the gap of using widely reported transcription factors to define characteristic high-expression genes in infancy that may be affected by early stress, and provides a key and effective combination of gene markers for early diagnosis of mental illness. Based on the genomics and epigenomics of genes specifically expressed in infancy, the present invention identifies key hub genes and transcription factors, and for the first time establishes that the MYT1L-SYT1 interaction gene combination can be used as an early detection strategy for mental disorders.

[0027] like Figure 1 As shown, the method provided by the present invention is divided into 5 steps, including (1) data collection (2) data processing and screening to obtain genes highly expressed in infancy (3) screening of genes with risk of mental illness among genes highly expressed in infancy (4) screening of transcription factors of genes with risk of mental illness (5) using the screened core transcription factors to obtain a gene set for early diagnosis of mental illness. The following are the detailed steps:

[0028] Step 1: Data Collection

[0029] The present invention obtains the brain gene expression data of 42 donors from the Allen Brain Science Institute (Allen Brain Map). These data include information from different age groups, covering the prenatal and postnatal stages.

[0030] The dataset was divided into eight different developmental stages. These stages were determined based on the age and developmental stage of the donor at the time of sample collection. The sample groups were categorized as follows: early prenatal (8-12 weeks of embryonic development), mid-prenatal (13-24 weeks of embryonic development), late prenatal (25-38 weeks of embryonic development), infancy (after birth-18 months of age), early childhood (19 months-5 years of age), childhood (6-11 years of age), adolescence (12-19 years of age), and adulthood (20-40 years of age).

[0031] Step 2: Data processing and screening to obtain highly expressed genes in infancy

[0032] Clust was used to identify high-precision co-expressed gene clusters specific to the eight developmental stages, thereby obtaining a set of genes with high expression characteristics during infancy. Figure 2As shown, the results revealed a unique co-expression cluster (Cluster 3) containing 897 genes that were highly expressed during infancy, and these Cluster 3 genes were enriched in functions related to the nervous system.

[0033] Step 3: Screening for psychiatric disease risk genes among genes highly expressed in infancy

[0034] Using GWAS information from the publicly available GWAS Catalog linked data, we narrowed our focus to specific gene sets associated with 10 psychiatric disorders.

[0035] In addition, a list of genes affected by de novo mutations in psychiatric disorders was obtained from the public PsyMuKB database.

[0036] By mapping the genes in different co-expression clusters in step 2 to these two gene datasets related to mental illness. Figure 3 As shown, a set of genes at risk for mental illness was screened out from genes highly expressed in infancy.

[0037] Step 4: Screening for transcription factors of neurological disease risk genes

[0038] Transcription factor enrichment analysis was performed using the public ChEA3 database, which includes transcription factor-target gene association information from ENCODE, ReMap, ARCHS4, GTEx, and Enrichr. Based on the significant results of the enrichment information, a set of transcription factors for genes at risk of infantile mental illness was obtained, among which the top 15 transcription factors covered the regulatory interactions of more than 60% of the genes.

[0039] Step 5: Use the screened core transcription factors to obtain a gene set for early diagnosis of mental illness

[0040] like Figure 4 As shown, through computational analysis of gene clusters, MYT1L emerged as a potential central transcription factor controlling these genes, therefore, the top-ranked transcription factor MYT1L was used as the core transcription factor.

[0041] The SYT1 gene, which is regulated by MYT1L, was evaluated using the human accelerated regions (HAR) to show that the SYT1 gene is species-conservative and may play an important role in the development of the human brain. The above results indicate that the MYT1L-SYT1 interaction gene combination can be used as a gene set for the diagnosis of early mental illness.

[0042] Therefore, the present invention is the first to implement the method of determining gene markers of mental illness by influencing gene expression patterns through transcription factors.

[0043] In this specification, the present invention has been described with reference to specific embodiments thereof. However, it is apparent that various modifications and variations may be made without departing from the spirit and scope of the present invention. Therefore, the specification and drawings should be regarded as illustrative rather than restrictive.

Claims

1. Use of a reagent for detecting the expression level of a biomarker in the preparation of a product for screening for increased risk of mental illness due to stress during infancy, characterized in that: The biomarker is a MYT1L-SYT1 interaction gene combination.

2. A method for screening biomarkers for increased risk of mental illness due to stress in infancy and childhood, characterized in that: Based on the genomics and epigenomics of genes specifically expressed in infancy and early childhood, hub genes and transcription factors are identified as biomarkers for screening for increased risk of mental illness due to external stress in infancy and early childhood.

3. The method according to claim 2, characterized in that The method comprises the steps of: (1) Collect brain gene expression data from donors at eight different developmental stages; (2) Data processing and screening to obtain genes with high expression in infancy and childhood; (3) Screening for psychiatric disease risk genes among genes highly expressed during infancy and childhood; (4) Screening for transcription factors of neurological disease risk genes; (5) Use the screened core transcription factors to obtain a gene set for early diagnosis of mental illness.